
SEO, Influencers And Good Content: How To Grow Your Company’s Online Presence
Carm Lyman is President of Lyman Agency . Getty We live in a digital world that em...
Read More
Social media marketing classes can give you the tools and strategies to reach your marketing goals if you are looking to boost...
Social Media Marketing, Social Media in Business, Social Media Strategy
Make the highest money online from Modern Instagram Marketing
Upon its acquisition of BayMedica LLC last year, InMed Pharmaceuticals Inc.(Nasdaq: INM) made the executive decision to forge a new path alongside its traditional domain in pharmaceutical drug development. With the acquisition long since closed, the end results are starting to bear fruit. The company has already launched B2B sales of the rare cannabinoid cannabidivarin (CBDV) in the U.S. health and wellness sector. This is but a preview of additional product launches that will be introduced to market in the coming quarters.Next up THCV is a cannabinoid chemical found in cannabis that shares similarities to in molecular structure to THC, according to Jordan Tishler, M.D., a cannabis therapeutics specialist, instructor of internal medicine at Harvard Medical School, president of the Association of Cannabinoid Specialists, and CEO/CMO at inhaleMD. THCV has some structural elements that are different, which contribute to different effects.__________________________________________________________Timestamps:0:00 Intro 1:03 BayMedica Acquisition1:53 What Problems InMed Is Solving For Industry By Synthesizing Rare Cannabinoids At Scale4:43 The Importance Of CBD-V And THC-V6:59 InMed Is Positioned To Become The First Company To Provide THCV To Market At Commercial Scale8:37 InMed Pharmaceuticals CEO Eric Adams Believes THCV The Cannabinoid Market Will Be Substantial11:35 The Difference Between Delta 9 And Delta 8 12:54 Expectations On Cannabis Space15:26 What Exactly Is An Analogue And The Importance Of It All?17:57 Ongoing Discussions With BayMedica Related To The Industry20:19 Jazz Pharmaceuticals Agreement To Acquire GW Pharmaceuticals For $220.00 Per American Depositary Share (ADS) For $7.2B21:47 Finalizing __________________________________________________________About Channel:We are a business news platform that provides the latest and best insight on the stories making headlines around the world. We give Institutional and retail investors an inside edge in the competitive world of investing and profile companies that are making waves in their ever-growing industries.We are The Dales Report.Check out our website: https://thedalesreport.com/Subscribe to our channel at https://article.thedalesreport.com/yo...Connect with us on our social media handles:Twitter: https://twitter.com/TheDalesReportInstagram: https://www.instagram.com/thedalesrep...Tiktok: https://www.tiktok.com/@thedalesrepor...Facebook: https://www.facebook.com/thedalesreportTDR Contributors Instagram: Nicolle Hodges: https://www.instagram.com/nicolledoublel/ Anthony Varrell: https://www.instagram.com/anthonyvarrell/_________________________________________________The Dales Report Inc. disclosure policy applies to this video: https://thedalesreport.com/disclosure/
Carm Lyman is President of Lyman Agency . Getty We live in a digital world that em...
Read MoreIn May 2020, a one-minute video tugged on the heartstrings of locked-down viewers all over the worl...
Read More